All Updates

All Updates

icon
Filter
Management news
Lykos Therapeutics announces 75% workforce layoff and board restructuring amid FDA rejection
Psychedelic Medicine
Aug 15, 2024
This week:
Partnerships
T-Mobile partners with OpenAI to develop AI-powered customer service platform
Generative AI Applications
Today
Partnerships
Runway partners with Lionsgate to develop AI video tools using studio's movie catalog
Generative AI Applications
Yesterday
Funding
QMill raises EUR 4 million in seed funding to provide quantum computing industrial applications
Quantum Computing
Yesterday
Product updates
QuiX Quantum launches 'Bia' quantum cloud computing service for quantum solutions
Quantum Computing
Yesterday
Partnerships
Oxford Ionics and Infineon Technologies partner to build portable quantum computer for Cyberagentur
Quantum Computing
Yesterday
Partnerships
Product updates
Tencent Ai Lab launches EzAudio AI for text-to-audio generation with Johns Hopkins University
Foundation Models
Yesterday
Funding
TON secures USD 30 million in investment from Bitget and Foresight Ventures
Web3 Ecosystem
Yesterday
Funding
Hemi Labs raises USD 15 million in funding to launch blockchain network
Web3 Ecosystem
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Machine Learning Infrastructure
Yesterday
Product updates
Fivetran launches Hybrid Deployment for data pipeline management
Data Infrastructure & Analytics
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Aug 15, 2024

Lykos Therapeutics announces 75% workforce layoff and board restructuring amid FDA rejection

Management news

  • Lykos Therapeutics is laying off about 100 employees, roughly 75% of its workforce, following the FDA's rejection of its approval request. The restructuring aims to support the company's efforts to refile an approval application.

  • The remaining skeleton team will focus on ongoing clinical development, medical affairs, and FDA engagement. The company also appointed David Hough, a former Johnson & Johnson executive, to oversee the clinical development program and FDA engagement for the planned resubmission.

  • Furthermore, Founder Rick Doblin has resigned from Lykos' board to focus on advocacy work. A newly formed independent advisory board will support management during the resubmission process and maintain contact with behavioral health facilities and key patient stakeholder groups.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.